• LAST PRICE
    3.8500
  • TODAY'S CHANGE (%)
    Trending Up0.2400 (6.6482%)
  • Bid / Lots
    3.8500/ 5
  • Ask / Lots
    3.8600/ 11
  • Open / Previous Close
    3.6200 / 3.6100
  • Day Range
    Low 3.6200
    High 3.8800
  • 52 Week Range
    Low 1.3700
    High 9.8000
  • Volume
    203,912
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 3.61
TimeVolumeKOD
09:32 ET37823.655
09:34 ET23233.71
09:36 ET14003.7405
09:39 ET10003.7601
09:41 ET10003.75
09:43 ET3003.76
09:45 ET2003.735
09:48 ET7003.76
09:50 ET5003.76
09:52 ET12003.74
09:54 ET1003.73
10:01 ET5003.75
10:03 ET6003.76
10:06 ET19003.78
10:08 ET6003.8
10:10 ET5003.8
10:12 ET9003.78
10:14 ET18013.76
10:15 ET11003.7811
10:17 ET3003.78
10:19 ET1003.76
10:28 ET3413.785
10:30 ET2503.79
10:32 ET10003.786
10:33 ET1003.79
10:35 ET5003.79
10:37 ET6003.794
10:44 ET5003.78
10:50 ET6003.785
10:53 ET2003.775
10:55 ET1003.78
10:57 ET2053.775
11:00 ET2003.78
11:04 ET1003.79
11:06 ET1003.79
11:08 ET2003.79
11:09 ET4003.795
11:11 ET1003.79
11:20 ET1003.8
11:22 ET1003.8
11:24 ET29913.805
11:26 ET1003.82
11:27 ET2503.8121
11:29 ET20983.815
11:31 ET35123.8401
11:33 ET10003.85
11:36 ET10093.81
11:38 ET1003.81
11:42 ET47003.77
11:47 ET74023.81
11:51 ET3003.81
11:54 ET1003.82
11:56 ET4003.83
11:58 ET7003.84
12:00 ET1383.83
12:02 ET4673.85
12:03 ET6003.85
12:05 ET59603.8
12:07 ET2003.8004
12:12 ET2003.81
12:16 ET1003.82
12:18 ET1003.82
12:21 ET13003.84
12:23 ET1003.84
12:25 ET3003.84
12:27 ET4003.84
12:30 ET1193.83
12:32 ET2993.8315
12:34 ET18003.835
12:39 ET1123.835
12:41 ET12003.85
12:48 ET1003.86
12:50 ET2293.8624
12:52 ET1003.87
12:54 ET3503.87
12:56 ET1003.87
12:57 ET14003.84
12:59 ET9033.85
01:03 ET15973.84
01:12 ET28973.85
01:15 ET2003.85
01:17 ET1003.855
01:19 ET5243.855
01:21 ET6003.86
01:24 ET4123.865
01:26 ET3003.87
01:28 ET11643.85
01:33 ET1003.8466
01:35 ET29003.85
01:42 ET3673.84
01:44 ET5003.84
01:46 ET25003.81
01:48 ET1003.81
01:51 ET2003.81
01:53 ET312943.8
01:55 ET1003.8
01:57 ET21003.81
02:02 ET1003.83
02:04 ET3003.83
02:06 ET36963.82
02:08 ET18723.82
02:09 ET20003.8199
02:11 ET16003.8251
02:13 ET12003.8297
02:15 ET11003.835
02:18 ET22853.85
02:20 ET6043.86
02:22 ET3003.86
02:24 ET2003.86
02:26 ET2003.86
02:27 ET2503.8519
02:29 ET2003.86
02:31 ET2003.86
02:36 ET124653.875
02:38 ET8683.875
02:40 ET22893.84
02:45 ET15003.845
02:49 ET1003.845
02:54 ET14693.86
02:56 ET6493.86
02:58 ET13003.87
03:00 ET59803.835
03:02 ET1003.84
03:03 ET6233.84
03:07 ET35973.86
03:09 ET2003.86
03:12 ET1003.86
03:14 ET2003.86
03:16 ET38363.85
03:18 ET12243.86
03:20 ET1003.87
03:21 ET2003.87
03:23 ET12253.86
03:25 ET1003.85
03:27 ET13003.85
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKOD
Kodiak Sciences Inc
189.7M
-0.8x
---
United StatesBOLD
Boundless Bio Inc
191.0M
-4.2x
---
United StatesGALT
Galectin Therapeutics Inc
187.6M
-4.0x
---
United StatesTRVI
Trevi Therapeutics Inc
192.3M
-8.1x
---
United StatesATOS
Atossa Therapeutics Inc
186.7M
-6.2x
---
United StatesINMB
INmune Bio Inc
198.0M
-5.8x
---
As of 2024-05-13

Company Information

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Contact Information

Headquarters
1200 PAGE MILL RDPALO ALTO, CA, United States 94304
Phone
650-281-0850
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder
Victor Perlroth
Chief Financial Officer, Executive Vice President, Secretary
John Borgeson
Lead Independent Director
Robert Profusek
Independent Director
Felix Baker
Independent Director
Charles Bancroft

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$189.7M
Revenue (TTM)
$0.00
Shares Outstanding
52.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.46
EPS
$-4.97
Book Value
$5.06
P/E Ratio
-0.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.